Authors: Biermasz, NR Hamdy, NAT Janssen, YJH Roelfsema, F

Citation: Nr. Biermasz et al., Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: A randomized controlled trial, J CLIN END, 86(7), 2001, pp. 3079-3085

Authors: Smit, JWA Janssen, YJH Lamb, HJ van der Wall, EE Stokkel, MPM Viergever, E Biermasz, NR Bax, JJ Vliegen, HW de Roos, A Romijn, JA Roelfsema, F

Citation: Jwa. Smit et al., Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass, J CLIN END, 86(10), 2001, pp. 4638-4643

Authors: Janssen, YJH Helmerhorst, F Frolich, M Roelfsema, F

Citation: Yjh. Janssen et al., 28th International symposium on GH and growth factors in endocrinology andmetabolism - Proceedings of a meeting held in Boston, Massachusetts, October 1999, GROWTH H I, 10, 2000, pp. 133-172

Authors: Janssen, YJH Helmerhorst, F Frolich, M Roelfsema, F

Citation: Yjh. Janssen et al., A switch from oral (2 mg/day) to transdermal (50 mu g/day) 17 beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency, J CLIN END, 85(1), 2000, pp. 464-467

Authors: Janssen, YJH Frolich, M Roelfsema, F

Citation: Yjh. Janssen et al., The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency, BR J CL PH, 47(3), 1999, pp. 273-278

Authors: Janssen, YJH Doornbos, J Roelfsema, F

Citation: Yjh. Janssen et al., Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency, J CLIN END, 84(1), 1999, pp. 279-284